Peer-reviewed veterinary case report
Effectiveness of sarolaner for treating dog demodicosis in Europe
By Becskei, Csilla et al.·Published in Veterinary dermatology·2018·Zoetis·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and safety of sarolaner against generalized demodicosis in dogs in European countries: a non-inferiority study.
- Species:
- dog
Plain-English summary
A group of dogs with generalized demodicosis, a skin condition caused by mites, were treated with either an oral medication called sarolaner or a topical treatment combining moxidectin and imidacloprid. After three to five monthly doses of sarolaner, 93% to 100% of the dogs showed no live mites, while the topical treatment had a lower success rate of 77% to 92% over a similar period. Both treatments significantly improved the dogs' skin conditions, but sarolaner was found to be just as effective and safer. Overall, dogs treated with sarolaner had a much greater reduction in skin lesions and no side effects were reported.
People also search for: dog skin mites treatment · sarolaner for demodicosis · moxidectin imidacloprid comparison · dog skin problems · effective treatments for dog skin conditions
Abstract
BACKGROUND: Treatment of canine demodicosis can be challenging; new treatments are always being sought. OBJECTIVE: The efficacy of sarolaner was evaluated in comparison with a moxidectin/imidacloprid topical product against generalized demodicosis in dogs in a randomized, single-masked, multi-centre field study. ANIMALS: Client-owned dogs were treated monthly with oral sarolaner (n = 53) or with weekly/monthly topical moxidectin/imidacloprid (n = 28). METHODS: Mites were counted monthly in deep skin scrapings and the severity of skin lesions was evaluated. Dogs completed the study when no live mites were found on two consecutive monthly skin scrapings or on day 180 at the latest (study end). RESULTS: Parasitological cure, defined as the first time that no live mites were found in the skin scrapings, was achieved in 92.9% and 100% of the dogs after three and no more than five monthly treatments with sarolaner (respectively). In the moxidectin/imidacloprid group, 77.3% and 91.7% of the dogs were cured after three and six months, respectively. Parasitological cure rate for sarolaner was non-inferior to moxidectin/imidacloprid on day 60. Mite counts were reduced by 77.2%, 95.0%, 98.5%, 99.0%, 100% and 100% in the sarolaner group and by 68.0%, 88.4%, 91.1%, 92.7%, 73.9% and 82.2% in the moxidectin/imidacloprid group, on days 30, 60, 90, 120, 150 and 180, respectively, compared to pre-treatment counts. The skin lesions improved throughout the study; the total affected body surface decreased by 94% in the sarolaner and by 72% in the moxidectin/imidacloprid group. There were no treatment-related adverse events. CONCLUSIONS: Monthly oral administration of sarolaner was safe and highly effective in the treatment of generalized demodicosis in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29423956/